Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EINSTEIN CHOICE
NL-OMON41605Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Sep 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivaroxaban and aspirin in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (3 arms), sponsored by Bayer. Started Sep 2014; status: active, not recruiting.
02
Drugs
rivaroxabanaspirin
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NL-OMON41605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41605.